INTRODUCTION
The identification and validation of novel drug targets continues to be a major bottleneck in drug development. The advent of high-throughput analysis of gene function using short interfering RNA (siRNA)-based screens provides an efficient means to predict novel functions of gene products in cellular signaling pathways and to identify potential drug targets (1, 2) .
A portion of the human genome has been identified that encodes proteins with functions that are predicted to be or are targets for drugs used for human diseases; this socalled druggable genome comprises between 3,000-10,000 genes (3, 4) . The products of these genes include protein classes such as kinases, G-protein coupled receptors (GPCRs), phosphatases, proteases, and ion channels (3) . It has been hypothesized that by focusing on the druggable genome, the likelihood of finding useful drug targets for human diseases could be increased.
The identification and development of radioprotectors (administrated prior to irradiation) and mitigators (administrated after irradiation but before clinical syndromes are detected) is of considerable importance because of the possible applications in clinical radiotherapy, after accidental exposure to radiation, and in radiation counterterrorism (5) .
In the present study, we tested the hypothesis that wellcharacterized drugs might have radioprotective effects. Using a synthetic protection assay, we screened siRNAs that were nontoxic in vitro for protective effects against a cytotoxic dose of ionizing radiation. We used a siRNA CACNA1B   CAMK2B   CAPN13  CAPN2  CAPNS2  CARD9  CATSPER2  CHRNA1  CHRNB2  COX8A  CSNK1G2  CTSA  CYP3A5  DGKQ  DMPK  DUSP22  DYPK1B   ECE1  ENPP3  EPHA1  EPHB2  FOLR1  GABRD  GALK2  GCDH  GRM8  H6PD   HARS2  IBSP   KCNE2   KCNG1   KCNK4  KCNK9  KLK5  LMLN  MAPKAPK2  MC2R  MED16  MLKL  MMP27  MMP3 PDE11A  PDE2A  PDE4B  PDE4D  PDE6C   PIGH   PIP5K1B   PKIA   PRPS1L1  PRSS1  PTPN9  PTPRA  REV1  RFPL3  ROR2  SKP2  SLC10A1  SLC15A1   SLC16A3  SLC17A5   SLC18A2   SLC19A1  SLC1A6  SLC25A22  SLC27A3   SLC44A5  SLC4A9  SLC6A1  SLC6A2  SLC6A3  SLCO4C1   SRM  STK24  STK39   STX11  STX4  TAP1   TGFB1/1   TLL2  TMEM 11  TMPRSS9  TRIB3  TRMT1 propionyl Table 1 ) that are known to encode gene transcripts considered to be actual or potential drug targets or to modify disease. We discovered that the commonly used hypoglycemic agent glyburide protected mice against total-body irradiation. These results illustrate the power of a combined approach of high-throughput siRNA screening and conventional cell-based assay to identify new radioprotectors.
MATERIALS AND METHODS

Reagents
The DharmaFECT 2 transfection reagent and 53 siRNA resuspension buffer were from Dharmacon (Lafayette, CO). The cell Titer-Blue Cell Viability Assay was from Promega (Madison, WI). The 384-well tissue-culture treated microtiter plates were from Greiner Bio-One (GmbH, Frickenhausen, Germany). OptiMEM, MEM and FBS were from Invitrogen (Carlsbad, CA). The Silencer Druggable Genome siRNA Library (Version 1.1) was from Ambion (Austin, TX). The Annexin V kit was from Biovision (Mountain View, CA). The lactate dehydrogenase (LDH) viability kit was from Sigma (St. Louis, MO). Rabbit polyclonal anti-ABCC8 antibody was from Abcam (Cambridge, MA). Mouse monoclonal anti-actin antibody was purchased from Sigma (A3853).
Cell Culture
Human glioblastoma T98G and U-87 MG cells (American Type Culture Collection, Manassas, VA) were maintained in MEM supplemented with 2 mM glutamine, 10% FBS and penicillinstreptomycin. Human primary astrocytes were purchased from ScienCell (Carlsbad, CA) and maintained according to the manufacturer's instructions. Normal human lung epithelial BEAS-2B cells were from American Type Culture Collection and were cultured in a serum-free bronchial epithelial growth medium (Lonza, Walkersville, MD). The 32D cl3 mouse hematopoietic progenitor cell line, dependent for growth upon interleukin 3 (IL-3), has been described previously (6) . 32D cl3 cells were passaged in fresh RMPI 1640 medium containing 10% FBS, 1% glutamine, penicillin-streptomycin and 15% WEHI-3 conditioned medium as a source of IL-3.
High-Throughput siRNA Delivery by Reverse Transfection
Human glioblastoma T98G cells were reverse transfected (7) with the siRNA library in 384-well plate at a final concentration of 20 nM/ target in a one-gene, one-well format. The siRNA complexes were prepared by mixing DharmaFECT 2 transfection reagent with a pool of three unique siRNA duplexes (each designed against a different region of the target transcript) per well in OptiMEM serum-free medium. T98G cell suspensions in culture medium were added (350 cells/well) directly onto the siRNA complexes. The siRNA-containing medium was replaced with fresh complete culture medium 5 h later. Cells were incubated for 48 h to allow for gene silencing (8) 
Threshold for Selecting Primary Radioprotective siRNA
The radiation siRNA screen was performed three times over three separate weeks. A candidate radioprotective siRNA was identified if the siRNA protected T98G cells $15% from radiation-mediated cell death in each of three independent screens.
Western Blot Analysis
T98G cells (2 3 10 5 /well) were reverse transfected in six-well plates using an ABCC8 duplex siRNA cocktail (10, 20 and 40 nM final concentration) or scrambled control siRNA (Ambion Silencer Negative Control no. 3 siRNA, 20 nM final concentration) using DharmaFECT 2 transfection reagent according to the manufacturer's instructions. After 48 h incubation, harvested cells were lysed on ice for 30 min in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% IGEPA, 0.5% sodium deoxycholate, 0.1% SDS in the presence of proteinase inhibitors) and then centrifuged at 10,000g for 5 min. The resulting supernatants were subjected to 8% SDS-PAGE and then transferred to a nitrocellulose membrane. The membrane was cut into two sections according to the position of molecular markers and then probed with anti-ABCC8 and antiactin (loading control), respectively, followed by horseradish peroxidase-coupled detection.
Validation of siRNA Detected Targets with a Cell-Based Assay
For target validation experiments, cells were seeded in 35-mm dishes at a density of 1 3 10 5 /dish and allowed to attach overnight. Cells were incubated with drugs in fresh culture medium at the indicated concentrations 1 h before or 30 min after irradiation. Cells were c-irradiated (10 Gy) with a Shepherd model 143-45A irradiator (J. L. Shepherd & Associates, San Fernando, CA) at a dose rate of ,4 Gy/min. The viabilities of cells were determined using the phosphatidylserine (PS) externalization/propidium iodide (PI) permeabilization assay or the LDH assay after 72 h postirradiation incubation. 
LDH assay
For human primary astrocytes, cell viability was determined using an LDH viability kit activity according to the manufacturer's instructions (Sigma). The enzyme activity from the culture medium and floating cells were used as an index of cell death. The adherent cells were lysed in 0.5% Triton X-100 and assayed for LDH activity. This cell-associated LDH activity was then added to the LDH activity in the culture medium. The amount of LDH present in the medium was calculated as a percentage of the total, which was then used to estimate the percentage of cell death in the corresponding samples.
In Vitro Radiation Survival Curves
Murine hematopoietic progenitor cells 32D cl3 cells were incubated with 10 mM glyburide 1 h before or after irradiation by adding glyburide to the IL-3-supplemented semisolid methycellulose-containing medium in which the cells were incubated for colony assay. The cells were irradiated with 0-8 Gy and incubated at 37uC for 1 week, at which time colonies of greater than 50 cells were counted (9, 10) . The data were fitted using the single-hit, multitarget model (9, 10).
Animal Welfare
All animal protocols were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and were performed under the supervision of the Division of Laboratory Animal Research of the University of Pittsburgh. Veterinary care was provided by the Division of Laboratory Animal Research of the University of Pittsburgh.
Survival of Irradiated Mice
To determine the effect of glyburide in a model of radiation-induced hematopoietic syndrome, we carried out total-body irradiation of mice as described previously (10) . Glyburide was dissolved in a 50:50 solution of cremophor EL and ethanol that was then diluted 1:4 in water. Female C57BL/6NHsd mice (15 per group) were injected intraperitoneally with 5 or 10 mg/kg glyburide (in two independent experiments) either 10 min before or 10 min after the LD 50/30 dose (9.5 Gy) of irradiation. Other groups of mice were irradiated control mice and vehicle-only treated, irradiated mice. Mice were followed for the development of the radiation-induced hematopoietic syndrome as demonstrated by a loss of weight and decreased activity, at which time they were euthanized according to Institutional Animal Care and Use Committee protocols.
Statistics
All data were expressed as the means ± SD of at least three independent experiments. Data from the in vitro radiation survival curves were analyzed with Student's t test, while the mouse survival data were analyzed by a log rank test (9) (10) (11) . Statistical comparisons between different groups were performed with Student's t test. P , 0.05 was considered significant.
RESULTS
An Automated Druggable Genome Radioprotective siRNA Library Screen
We used a high-density 384-well plate format and large-scale siRNA screen to rapidly and robustly identify genes that modulate the response of human glioblastoma T98G cells to ionizing radiation. Employ- siRNA SCREEN REVEALS GLYBURIDE AS A RADIOPROTECTOR ment of relatively radioresistant T98G cells (12) provided the advantage of screening to identify both radiosensitizing and radiation resistance-inducing genes.
The 6-day workflow of the siRNA screening is illustrated in Supplementary Fig. 1 . siRNA molecules (final concentration 20 nM) were added to the wells, targeting one gene per well. In-plate scrambled siRNA control wells were included on every plate. For each of the 5,520 genes, we pooled three unique siRNA duplexes to reduce the cost and improve throughput. Transfection complexes were prepared using automated liquid handling instruments, and after a 15-20-min incubation they were divided between two new 384-well plates followed by the addition of T98G cells in suspension. Plate pairs were incubated for 48 h before irradiation (25 Gy) or mock treatment. Seventy-two hours later, cell viability was measured by the CellTiter-Blue assay. The dose of 25 Gy was chosen to reduce the control cell viability by approximately 50%. Based on data from three independent siRNA screens, we identified 116 genes that, when silenced, protect T98G cells from c radiation (Table 1) . Among these genes were transporters, kinases, transcription regulators, transmembrane receptors, G-protein coupled receptors, phosphatases, ion channels and peptidases (Table 1 and Fig. 1) . Figure 2 illustrates a protective siRNA that silenced ATP-binding cassette, subfamily C, member 8 (ABCC8). The down-regulation of ABCC8 protein levels was confirmed by Western blotting. Silencing of ABCC8 with siRNA duplexes exerted no detectable effect on the viability of T98G cells, while 25 Gy decreased cell viability by 55%. Silencing of ABCC8 48 h prior to irradiation reproducibly protected cells by 35%.
Target Validation using Small Molecule Inhibitors
From the 116 identified siRNAs, we focused on 13 candidate siRNA gene transcripts for further study because of the ready availability of drugs that targeted the gene product functionality ( Table 2) . Two of the candidate siRNA gene transcripts, PDE4D and PDE4D, shared a common inhibitor, rolipram, and three candidates, ABCA4, ABCA8 and ABCC8, shared glyburide as an inhibitor. The radioprotective effects of these 10 indentified compounds were tested against control and irradiated T98G cells, which were initially used in the siRNA screen. Radiation-induced cell death was determined by PS externalization and PI permeability using flow cytometry. Around 30% of cells displayed externalized PS and/or increased membrane permeability after 72 h postirradiation incubation. Glyburide (Fig. 3) , a second-generation sulfonylurea used clinically for type II diabetes, attenuated radiation-induced cell death in a concentration-dependent manner (12.5-200 mM) when administered 1 h prior to irradiation (Fig. 3) . Moreover, glyburide protected cells from radiation-induced apoptosis to a similar extent when administered 30 min after c irradiation (Fig. 4A) . Treatment of cells with 200 mM glyburide effectively protected cells over a range of radiation doses (Fig. 4B) . The other nine chemicals tested showed no protective effect against radiationinduced cell death (Fig. 3) .
In Vitro Radioprotection in Different Cell Phenotypes
To further explore the radioprotective effect of glyburide, we extended the screening test to six other histologically distinct human cell lines: glioblastoma U-87 MG, cervical adenocarcinoma HeLa, lung carcinoma H1299, permanent bone marrow stromal cell line KM101, bronchial epithelial cells BEAS-2B, and human primary astrocytes. Cells were exposed to 10 or 25 Gy based on their radiosensitivity as determined by the Annexin V assay. Glyburide protected U-87 MG and BEAS-2B cells and human primary astrocytes (Fig. 4C, D) . Glyburide had no detectable effect on c-irradiated H1299, HeLa or KM101 cells (data not shown).
In Vitro Clonogenic Radiation Survival Curves
The radioprotective effect of glyburide was next tested in a clonogenic survival assay. Cells of the murine hematopoietic progenitor cell line 32D cl3 were incubated in liquid culture with 10 mM glyburide for 1 h before irradiation (0-8 Gy) or by transferring the cells to semisolid methycellulose medium containing 10 mM glyburide after irradiation. Cells incubated in glyburide before irradiation were protected from radiation as seen by the increased shoulder on the radiation survival curve (n 5 34.9 ± 0.5 compared to 3.1 ± 1.3 or 2.5 ± 0.9 for control irradiated cells or cells incubated with glyburide after irradiation) (Fig. 5) . There was no significant difference in the D 0 (1.14 ± 0.20 Gy) compared to cells incubated in glyburide before or after irradiation (1.18 ± 0.13 and 1.10 ± 0.09 Gy, respectively).
In Vivo Total-Body Radioprotection against the Hematopoietic Syndrome
Mice were injected intraperitoneally with 5 or 10 mg/kg glyburide in two independent experiments either 10 min before or 10 min after 9.5 Gy total-body irradiation. The mice were followed for the development of bone marrow failure (Fig. 6 ). Mice injected with glyburide before irradiation were protected, seen as a significant increase in survival compared to irradiated control mice (90% of mice pretreated with 10 mg/kg glyburide survived compared to 42% of irradiated controls, P 5 0.02). Mice injected with glyburide after irradiation or with vehicle were not protected from radiation.
DISCUSSION
The present data show that siRNA library screening affords an unbiased method for large-scale and rapid target identification. It has been employed successfully to identify novel targets for cancer therapeutics in transformed human cells (13, 14) , especially in a synthetic lethal format (15) . There are no previous reports exploiting this technique to discover new radiation protectors. In the present study, we exploited the synthetic protective siRNA screening concept to identify genes that, when silenced, protected human glioblastoma cells from radiation-induced cell death. We identified 116 potential radioprotective genes by screening a human druggable genome library. Ten compounds with binding capacities to 13 candidate gene products were tested. One of the 10, glyburide, demonstrated in vitro and in vivo radioprotective effects.
Several of the 10 selected compounds are known to have multiple pharmacological targets, and disruption of these additional targets could have mitigated the cellular response to radiation. We found that several compounds increased the toxicity of radiation. Moreover, siRNA causes a loss of the entire protein while pharmacological agents generally target only the enzymatic activity of a translated protein. For this reason, it is often difficult to fully replicate results of siRNA with small molecules.
The specific mechanisms by which glyburide provides radioprotection are unknown. Sulfonylureas, including glyburide, are widely used in the treatment of diabetes mellitus and act to block ATP-sensitive potassium (K ATP ) channels, such as ABCC8 (16, 17) . The hypoglycemic actions of the sulfonylureas are due at least in part to their high affinity for binding the ABCC8, the sulfonylurea receptor 1 and subsequent inhibition of the pancreatic K ATP channel, which is essential for triggering insulin secretion via membrane depolarization (18) . Interactions of glyburide with sulfonylurea receptor 1 may explain its role in regulating radiation-induced apoptosis (19) (20) (21) . Apoptosis may be modulated by the regulatory effects of glyburide on K ATP channels, which siRNA SCREEN REVEALS GLYBURIDE AS A RADIOPROTECTOR control intracellular Ca 2z levels and may affect the mitochondrial permeability transition pore (21, 22) . Other drugs have been shown to act as regulators of this channel and to alter the cellular apoptosis program (21, 23) . Further studies will be required to evaluate the molecular mechanisms of radiation protection of glyburide and other potassium channel inhibitors.
The radioprotective effect of glyburide may have occurred through indirect interaction with other molecular targets. We demonstrated here that siRNA knockdown of ABCA4 and ABCA8 (ATP-binding cassettes members, subfamily A, member 4 and 8) protected T98G cells from radiation. Little information exists about the potential involvement of ABCA4 and ABCA8 in the apoptosis signaling pathway. Furthermore, their tissue expression is distinct from ABCC8. Since glyburide showed less protection of irradiated non-neuronal (central nervous system) H1299, HeLa and KM101 cells, the data may indicate that the radioprotective effect is cell phenotype specific. Molecular intermediate steps in this process are not yet identified. Since glyburide protected non-tumorigenic 32D cl3 cells in vitro as well as total-body-irradiated mice, the data are consistent with the hypothesis that the drug may provide normal tissue radioprotection.
Glyburide is an orally active, safe, clinically available drug used to treat type 2 diabetes. The maximal tolerated dose of glyburide has been established as 10 mg, twice daily, in patients ,65 years old or half the dose, 10 mg, daily, in patients $65 years old (24) . Since glyburide can produce severe hypoglycemia (25, 26) at high doses, it is encouraging that the doses of glyburide used in our study did not cause hypoglycemia in C57BL/ 6NHsd mice (data not shown). 
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While preirradiation treatment with glyburide effectively blocked radiation-induced apoptosis and improved survival, it lacked efficacy as a mitigator in mice after irradiation. We are currently developing different screening strategies using more radiosensitive human cells transfected with siRNA after irradiation to identify radiation mitigators with significant activity after irradiation.
The potential targets of action of glyburide may or may not be independent of DNA repair mechanisms associated with ionizing radiation. Gene products directly associated with DNA repair mechanisms have been shown to be targets for developing radioprotectors (27) (28) (29) ; however, other non-DNA repair targets have also been proposed (30) . Ionizing radiation initiates a variety of cellular signal transduction pathways distal to DNA damage that lead to cell death. Gene products associated with disruption of the mitochondrial electron transport chain, mitochondrial membrane oxidation, permeabilization of the mitochondrial outer membrane, and release of pro-apoptosis factors including cytochrome c may be targets for developing radioprotectors (9) . The present drug discovery process led to identification of some targets that appeared to be independent of DNA repair; however, indirect effects through DNA repair cannot be ruled out. Some DNA repair pathway-related gene products were identified in our list of positives (such as VAV3-guanine nucleotide exchange factor). However, inhibition of mRNA transcripts of DNA repair molecules by synthetic siRNA would be expected to confer radiosensitization rather than radiation resistance. In other experiments in which radiation-induced apoptosis increased above control levels, we would expect to find more siRNAs targeting mRNA encoded by DNA repair genes. In addition, mRNA and/or protein levels of many DNA repair gene products may not have been decreased under the current experimental conditions. We pursued further validation of the gene products indentified by the positive siRNA results. Finally, we used criteria for radiation protection that may have been so stringent that we missed detecting some DNA repair genes.
The present results demonstrate the power of unbiased siRNA screening with a druggable genome library and suggest that glyburide might be a clinically useful radioprotector. 
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FIG. 6.
Radioprotective effect of glyburide in total-body-irradiated mice. Mice were injected with glyburide 10 min before or 10 min after exposure to 9.5 Gy. Mice injected with glyburide before irradiation had a significantly increased survival compared to the control irradiated mice. Injection of glyburide after irradiation had no significant effect.
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